Dr. Lal PathLabs Ltd (LALPATHLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Dr. Lal PathLabs Ltd on NSE and BSE, with an AI summary of each filing.
Attached
Audio / Video · 05 Nov 2026, 1:34 am
Dr. Lal PathLabs Releases Q2 and H1 FY27 Earnings Call Audio Recording Dr. Lal PathLabs Limited has made available the audio recording of its Q2 and H1 FY27 earnings conference call conducted with investors and analysts on 4th Nov'26. The recording has been uploaded to the company's official website in compliance with Regulations 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Attached
Investor Presentation · 04 Nov 2026, 7:48 pm
Dr Lal PathLabs Reports Robust Q2 FY27 With 27.5% YoY PAT Growth Dr Lal PathLabs delivered strong Q2 FY27 performance, with revenue growing 19.6% YoY to INR 874 Cr, driven by a 13.6% YoY rise in sample volumes (28.8 Mn) and 9.0% YoY patient growth (9.0 Mn). EBITDA rose 25.1% YoY to INR 280 Cr, expanding margins by 140 bps to 32.1%. PAT increased 27.5% YoY to INR 194 Cr. H1 FY27 revenue reached INR 1,672 Cr (+19.4% YoY) with PAT of INR 364 Cr (+27.3% YoY). SwasthFit contributed 26% of Q2 revenue. Cash and equivalents stood at INR 1,746 Cr.
Attached
Press Release · 04 Nov 2026, 7:45 pm
Dr Lal PathLabs Q2 FY27 Consolidated Results Dr Lal PathLabs reported strong Q2 FY27 financial results, with consolidated revenue rising 19.6% YoY to Rs 874 Cr. EBITDA increased 25.1% YoY to Rs 280 Cr, expanding margins by 140 bps to 32.1%. PAT grew 27.5% YoY to Rs 194 Cr with a 22.2% margin, while EPS stood at Rs 11.5. The company declared an interim dividend of 50% (Rs 5 per share). Cash and cash equivalents reached Rs 1,746 Cr as of 30th Sep'26.
Attached
Change in Management · 04 Nov 2026, 7:18 pm
Dr. Lal PathLabs Reports Robust Q2 Performance and Declares Interim Dividend Dr. Lal PathLabs posted consolidated revenue from operations of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn. Consolidated net profit rose 27.4% YoY to INR 1,939 mn versus INR 1,522 mn in the prior-year period. The board declared a second interim dividend of INR 5 per share (50% on face value of INR 10) with a record date of 11th Nov'26, and approved further investments of up to INR 49.5 crore in wholly owned subsidiary Dr. Lal PathLabs FZCO.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026.
Outcome · 04 Nov 2026, 7:17 pm
Attached
Others (Uncategorized) · 04 Nov 2026, 7:12 pm
Dr Lal PathLabs Reports Robust Q2 FY27 Results and Declares Interim Dividend Dr Lal PathLabs posted a strong Q2 FY27 performance for the quarter ended 30th Sep'26, with consolidated revenue rising 19.6% YoY to INR 8,739 mn and net profit growing 27.4% YoY to INR 1,939 mn. Basic EPS expanded to INR 11.51 from INR 9.03 YoY. The Board declared a second interim dividend of INR 5 per share (record date: 11th Nov'26) and approved an investment of up to INR 49.5 cr in its wholly owned subsidiary, Dr. Lal PathLabs FZCO, Dubai.
Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates
Outcome · 04 Nov 2026, 7:09 pm
Attached
Dividend · 04 Nov 2026, 7:08 pm
Dr. Lal PathLabs Reports Strong Q2 Results, Declares Interim Dividend, and Expands Overseas Dr. Lal PathLabs reported consolidated revenue of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn, with net profit rising 27.4% YoY to INR 1,939 mn. Basic EPS expanded to INR 11.51 from INR 9.03. The Board declared a second interim dividend of INR 5 per share (50% on face value of INR 10), with a record date of 11th Nov'26. Additionally, the company approved up to INR 49.5 cr in further investments into its Dubai subsidiary to fund operations and African expansion.
Attached
Others · 04 Nov 2026, 7:07 pm
Dr. Lal PathLabs Reports Robust Q2 FY27 Results and Declares Interim Dividend Dr. Lal PathLabs reported consolidated revenue from operations of INR 8,739 mn for the quarter ended 30th Sep'26, up 19.6% YoY from INR 7,306 mn. Consolidated net profit rose 27.4% YoY to INR 1,939 mn, while basic EPS reached INR 11.51 compared to INR 9.03 in Q2 FY26. The board declared a second interim dividend of INR 5 per share (50% of face value) with a record date of 11th Nov'26, and approved an investment of up to INR 49.5 crore in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO.
Dr. Lal Path Labs Ltd. has informed the Exchange that Record date for the purpose of 2nd Interim Dividend is 11-Nov-2026.
Outcome · 04 Nov 2026, 7:06 pm
Attached
Dividend · 04 Nov 2026, 7:05 pm
Dr. Lal PathLabs Reports Strong Q2 FY27 Results and Declares Interim Dividend Dr. Lal PathLabs reported consolidated revenue of INR 8,739 Mn for the quarter ended 30th Sep'26, up 19.6% YoY and 9.6% QoQ. Consolidated net profit rose 27.4% YoY and 13.7% QoQ to INR 1,939 Mn. Basic EPS stood at INR 11.51 versus INR 9.03 in the year-ago period. The board declared a second interim dividend of INR 5 per share (50% on face value of INR 10) with a record date of 11th Nov'26, and approved investing up to INR 49.5 Cr in wholly owned subsidiary LPL Dubai.
Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.
Outcome · 04 Nov 2026, 7:04 pm
Attached
Financial Result · 04 Nov 2026, 7:03 pm
Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share.
Outcome · 04 Nov 2026, 7:02 pm
Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 6:59 pm
Attached
Outcome · 04 Nov 2026, 6:57 pm
Dr. Lal PathLabs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 8,739 (+19.6% YoY | +9.6% QoQ) ■ EBITDA: 2,801 (+25.0% YoY | +13.2% QoQ) ■ EBITDA Margin (%): 32.1 (+138 bps YoY | +103 bps QoQ) ■ PAT: 1,922 (+27.6% YoY | +13.4% QoQ) ■ EPS (INR): 11.5 (+27.3% YoY | +13.2% QoQ)
DR. LAL PATH LABS LTD. has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider Dividend.
Intimation · 27 Oct 2026, 10:33 pm
Attached
Intimation · 04 Nov 2026, 6:00 pm
Dr. Lal PathLabs Schedules Q2 & H1 FY27 Earnings Call for 4th Nov'26 Dr. Lal PathLabs Ltd. will host its Q2 & H1 FY27 earnings conference call on 4th Nov'26 at 6:00 PM IST to discuss financial and operating performance, following the results announcement on the same day. Key leadership, including Executive Chairman (Hony) Brig. Dr. Arvind Lal, CEO Shankha Banerjee, and Group CFO & CEO-International Business Ved Prakash Goel, will represent the company. Universal access dial-ins are +91 22 6280 1141 and +91 22 7115 8042, with international access available across the USA, UK, Singapore, and Hong Kong.
Attached
Dividend · 27 Oct 2026, 10:09 pm
Dr. Lal PathLabs Board to Consider Q2 Results and Second Interim Dividend Dr. Lal PathLabs Limited announced that its Board of Directors will meet on 4th Nov'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the Board will consider the declaration of a 2nd Interim Dividend on equity shares for FY27 during the same meeting.
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Update on board meeting
Intimation · 04 Nov 2026, 5:30 am
Dr. Lal PathLabs Board to Consider Q2 Results and Second Interim Dividend Dr. Lal PathLabs Limited announced that its Board of Directors will meet on 4th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the Board will evaluate the proposal for a second interim dividend on equity shares for FY26-27.
Attached
Others (Uncategorized) · 14 Oct 2026, 12:20 am
Dr. Lal PathLabs Subsidiary Fully Acquires Centrapath Labs for Cash Consideration Dr. Lal PathLabs announced that its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), acquired the remaining 30% equity stake in Centrapath Labs Private Limited (CPL) on 13th Oct'26, making CPL a wholly owned subsidiary of PUPL. The cash transaction was completed at INR 1,608.352 per share and is not a related-party transaction. Indore-based CPL operates in healthcare and diagnostic services, reporting turnovers of INR 20.5 crore in FY26, INR 23.7 crore in FY25, and INR 20.8 crore in FY24.
Attached
Others (Uncategorized) · 12 Oct 2026, 7:33 pm
Dr. Lal PathLabs Invests up to INR 30.3 Crores in Subsidiary PUPL Dr. Lal PathLabs has completed an additional cash equity investment not exceeding INR 30.3 Crores in its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), on 12th Oct'26. The capital infusion will fund PUPL's acquisition of the remaining 30% equity stake in CentraPath Labs Private Limited (CPL), making CPL a wholly owned subsidiary of PUPL. PUPL, operating in healthcare and diagnostic services, reported turnovers of INR 7.23 Crores in FY26, INR 7.10 Crores in FY25, and INR 7.28 Crores in FY24.
Attached
Others (Uncategorized) · 08 Oct 2026, 6:41 pm
Dr. Lal PathLabs Faces ITAT Appeal Over Disallowed ESOP Expenses Dr. Lal PathLabs received intimation on 7th Oct'26 regarding an Income Tax Department appeal before the Income Tax Appellate Tribunal (ITAT), New Delhi, for AY 2022-23. The department challenged a prior Commissioner of Income Tax (Appeals) order that granted relief to the company regarding disallowed ESOP expenses totaling INR 32,66,18,927. Management stated it does not expect the appeal's outcome to have any material financial or operational impact on the company.
Attached
Others (Uncategorized) · 02 Oct 2026, 1:02 am
Dr. Lal PathLabs Completes Acquisition of Stake in SN Genelab Dr. Lal PathLabs Limited has completed the acquisition of a stake in SN Genelab Private Limited on 1st Oct'26, pursuant to the terms and conditions of the definitive agreement. This follows the prior approval granted by the company's Board of Directors, which was formally disclosed to the exchanges on 24th Sep'26. All regulatory disclosures mandated under SEBI Listing Regulations were previously submitted.
Attached
Others (Uncategorized) · 26 Sept 2026, 10:25 pm
Dr. Lal PathLabs Completes 80% Stake Acquisition in Sunshine Healthcare Ghana Dr. Lal PathLabs Limited announced that its wholly-owned subsidiary, Dr Lal PathLabs FZCO, Dubai, has completed the acquisition of an 80% stake in Ghana-based Sunshine Healthcare Limited (SHL). Following the transaction, originally approved on 24th Jul'26 and completed on 26th Sep'26 in compliance with local Ghanaian regulations, SHL has officially become a step-down subsidiary of the company, expanding its international healthcare footprint.